Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2

Main Article Content

Lawrence Eichenfeld
Elaine Siegfried
Pearl Kwong
Susan Cutler
Cynthia Willson
Pamela Rumney
Christine Crosby
Jennifer Andres
Mark McBride

Keywords

molluscum, VP-102, lesion count

Abstract

N/A

References

1. Eichenfield L et.al. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021 Mar;22(2):257-265.

2. Eichenfield LF et. al. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Dec;156(12):1315–1323.